



*13 December, 2016*

## **ZenBio, Inc. Announces Licensing Agreement with Exoceleuticals**

**RESEARCH TRIANGLE PARK, NC** - ZenBio, Inc. today announced a non-exclusive licensing agreement with Exoceleuticals, Inc for its proprietary Zen3 Exosome technology. Exoceleuticals, has recently launched their first product line, eXO, debuting with their first product, eXO Face utilizing the Zen3 Exosomes technology.

Exosomes are a vital aspect of human biology. Exosomes are tiny messengers release by cells which communicate with surrounding cells using proteins, lipids, and nucleic acid fragments as their language. Recently, scientists have figured out how to isolate them from cell cultures and use them for different purposes. For instance, some researchers are studying how exosomes can help grow, repair, and regenerate specific tissue types. Our Zen3 Exosome technology is the cosmetic application of these repair and regenerate principles. Our exosomes sync cells to lock in hydration, while facilitating self-repair to reduce the outward appearance of aging. Dr. John W. Ludlow, PhD at ZenBio stated "With the current body of exosome data being reported by scientists in the field of tissue engineering and regenerative medicine, it was clear to me that these naturally-occurring bio-active particles have a great potential to rejuvenate and revitalize skin. Laboratory experiments conducted at ZenBio and at a contract company have confirmed this potential. Exoceleuticals has decided to be the first to market a cosmetic with isolated bio-active exosomes as the key active ingredient".

### **About ZenBio, Inc.**

**ZenBio, Inc.**, a privately held biotechnology company, is a leading provider of research tools for the study of human metabolic disease and skin-related disorders. Founded in 1995, the company performs contract research for major pharmaceutical, personal-care and biotechnology companies around the world. ZenBio established its ZenSkin® platform specifically to address the needs of dermatology researchers. The company provides full thickness skin, skin equivalents, skin-derived cells, related reagents and contract services to the biomedical research community. ZenBio also develops and commercializes research tools, and it leverages its expertise in this field as a contract research organization. ZenBio pioneered tissue engineering with adult adipose-derived stem cells and is currently expanding its product offering to address a variety of developmental and onset metabolic diseases such as obesity

### **About Exoceleuticals, Inc.**

**Exoceleuticals Inc** is a newly formed North Carolina corporation with offices in both RTP and NYC. The company's mission is to develop unique healthy skin solutions backed by the emerging science of exosome biology. Exoceleuticals has recently launched their first product line, eXO, debuting with their first product, eXO Face, available at [www.exoskinsimple.com](http://www.exoskinsimple.com) Exoceleuticals intends to extend its skin care line by adding a body lotion and men's moisturizer in 2017. They also are exploring programs that address a variety of skin issues involving inflammatory diseases such as acne, psoriasis and dermatitis.



For more information about ZenBio, Inc., go to [www.zen-bio.com](http://www.zen-bio.com) or contact:

Will Plentl, Chief Operating Officer

ZenBio, Inc.

Tel. (919)-547-0692; or 1-866-ADIPOSE

Email: [will@zenbio.com](mailto:will@zenbio.com)

[www.zenbio.com](http://www.zenbio.com)

####